Robert Lutz

Robert Lutz

Company: Iksuda Therapeutics

Job title: Chief Scientific Officer


Chairperson’s Opening Remarks 9:25 am

Read more

day: Day Two

Panel Discussion – Thinking Strategically About What Targets You Select 3:30 pm

Understanding where your target choice and ADC fits into the ADC and wider oncology landscape? How do you differentiate yourself through using improved linker-payload technologies on previously validated targets? Balancing risk in your pipeline through your target choice Novel targets or previously validated targets? Discussing the role of future HER2 ADCsRead more

day: Day One

The Vital Triad of ADC Design: Target, Indication & Payload 9:30 am

Reviewing how the selection of an ADC target requires consideration of the potential clinical indications and the mechanistic properties of available linker payloads Assessing how the availability of novel differentiated linker-payloads provides an opportunity to calibrate potential clinical success against validated clinical benchmarks Presenting case study examples to demonstrate integration of target selection, clinical indication…Read more

day: Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.